DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...

Per the terms of the agreement, Nanowear will use glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) synchronously alongside Nanowear’s previously FDA-cleared cardiovascular ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.